Fifth Circuit mifepristone prescribing rules hearing
Analysis based on 11 articles · First reported Sep 09, 2026 · Last updated Sep 09, 2026
The case could tighten mifepristone distribution, potentially reducing sales for manufacturers and increasing reliance on misoprostol-only regimens. A restrictive ruling may also affect telehealth abortion providers and pharmaceutical supply chains, though the Supreme Court's involvement and FDA review add uncertainty.
On September 9, 2026, the United States — United States Court of Appeals for the Third Circuit heard arguments in a case challenging the FDA's rules for prescribing mifepristone, a drug used in the most common abortion method. The case, brought by United States — Louisiana Attorney General Liz Murrill and Rosalie Markezich, seeks to restrict mifepristone to in-person dispensing, effectively banning telehealth prescriptions and mail delivery. The FDA, which is reviewing its rules, is a defendant. The Supreme Court previously blocked changes to the rules pending further review. The case is part of a broader legal effort by anti-abortion groups and several states to limit abortion pill access. The outcome could affect nationwide access to medication abortion, which accounts for at least 60% of U.S. abortions. The FDA has been ordered to provide a status update by October 7, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard